Targeting senescent cells alleviates obesity-induced metabolic dysfunction.

Palmer AK, Xu M, Zhu Y, Pirtskhalava T, Weivoda MM, Hachfeld CM, Prata LG, van Dijk TH, Verkade E, Casaclang-Verzosa G, Johnson KO, Cubro H, Doornebal EJ, Ogrodnik M, Jurk D, Jensen MD, Chini EN, Miller JD, Matveyenko A, Stout MB, Schafer MJ, White TA, Hickson LJ, Demaria M, Garovic V, Grande J, Arriaga EA, Kuipers F, von Zglinicki T, LeBrasseur NK, Campisi J, Tchkonia T, Kirkland JL. · 2019

Read Targeting senescent cells alleviates obesity-induced metabolic dysfunction. by Palmer AK, Xu M, Zhu Y, Pirtskhalava T, Weivoda MM, Hachfeld CM, Prata LG, van Dijk TH, Verkade E, Casaclang-Verzosa G, Johnson KO, Cubro H, Doornebal EJ, Ogrodnik M, Jurk D, Jensen MD, Chini EN, Miller JD, Matveyenko A, Stout MB, Schafer MJ, White TA, Hickson LJ, Demaria M, Garovic V, Grande J, Arriaga EA, Kuipers F, von Zglinicki T, LeBrasseur NK, Campisi J, Tchkonia T, Kirkland JL. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6516193.txt.

Introduction

Palmer and co-authors test whether clearing senescent cells eases obesity-linked metabolic harm. Their study appeared in Aging Cell. Senescent cells build up in the fat tissue of obese humans and rodents. Their causal role in diabetes was still unproven.

The team cut senescent cell burden in obese mice two ways. One used drug-activated suicide genes under the p16Ink4a promoter. The other used senolytic drugs such as dasatinib plus quercetin. Both routes improved glucose tolerance and insulin sensitivity. Inflammatory signals in blood fell, and fat formation improved. Kidney and heart measures also got better. The authors read senescence as a causal driver worth targeting.

Catalog record

CREATORPalmer AK, Xu M, Zhu Y, Pirtskhalava T, Weivoda MM, Hachfeld CM, Prata LG, van Dijk TH, Verkade E, Casaclang-Verzosa G, Johnson KO, Cubro H, Doornebal EJ, Ogrodnik M, Jurk D, Jensen MD, Chini EN, Miller JD, Matveyenko A, Stout MB, Schafer MJ, White TA, Hickson LJ, Demaria M, Garovic V, Grande J, Arriaga EA, Kuipers F, von Zglinicki T, LeBrasseur NK, Campisi J, Tchkonia T, Kirkland JL.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE62 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6516193

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Targeting senescent cells alleviates obesity‐induced metabolic dysfunction By Allyson K. Palmer, Ming Xu, Yi Zhu, Tamar Pirtskhalava, Megan M. Weivoda, Christine M. Hachfeld, Larissa G. Prata, Theo H. van Dijk, Esther Verkade, Grace Casaclang‐Verzosa, Kurt O. Johnson, Hajrunisa Cubro Published in: Aging Cell DOI: 10.1111/acel.12950 ABSTRACT Abstract Adipose tissue inflammation and dysfunction are associated with obesity‐related insulin resistance and diabetes, but mechanisms underlying this relationship are unclear. Although senescent cells accumulate in adipose tissue of obese humans and rodents, a direct pathogenic role for these cells in the development of diabetes remains to be demonstrated. Here, we show that reducing senescent cell burden in obese mice, either by activating drug‐inducible “suicide” genes driven by the p16Ink4a promoter or by treatment with senolytic agents, alleviates metabolic and adipose tissue dysfunction. These senolytic interventions improved glucose tolerance, enhanced insulin sensitivity, lowered circulating inflammatory mediators, and promoted adipogenesis in obese mice. Elimination of senescent cells also prevented the migration of transplanted monocytes into intra‐abdominal adipose tissue and reduced the number of macrophages in this tissue. In addition, microalbuminuria, renal podocyte function, and cardiac diastolic function improved with senolytic therapy. Our results implicate cellular senescence as a causal factor in obesity‐related inflammation and metabolic derangements and show that emerging senolytic agents hold promise for treating obesity‐related metabolic dysfunction and its complications. INTRODUCTION The prevalence of type 2 diabetes has quadrupled since 1980 (World Health Organization, 2016). It is associated with multi‐organ complications, including cardiovascular and renal disease. Obesity and, more specifically, dysfunctional adipose tissue are strongly associated with whole‐body insulin resistance and type 2 diabetes mellitus (Kahn & Flier, 2000; Palmer et al., 2015). Senescent cells accumulate in adipose tissue of obese and diabetic humans and mice (Minamino et al., 2009; Schafer et al., 2016; Tchkonia et al., 2010), but it is unclear whether they are merely associated with diabetes or if their presence is a causal driver. Cellular senescence is a cell fate that entails proliferative arrest and acquisition of a pro‐inflammatory senescence‐associated secretory phenotype (SASP; Coppe et al., 2008). Although senescent cells exist in relatively small numbers in any particular tissue, they have been associated with multiple diseases of aging and are emerging as useful therapeutic targets for age‐related diseases, including cardiovascular disease, pulmonary fibrosis, neurodegeneration, and osteoporosis (Farr et al., 2017; Musi et al., 2018; Roos et al., 2016; Schafer et al., 2017). A number of stimuli, including potentially oncogenic, inflammatory, damage‐related, and metabolic stimuli, can trigger a senescence response (Munoz‐Espin & Serrano, 2014). Components of the SASP secreted by adipose‐derived senescent cells have been postulated to confer insulin resistance upon metabolic tissues, inhibit adipogenesis, and attract immune cells that can exacerbate insulin resistance (Xu, Palmer et al., 2015). Here, we determined whether removing senescent cells in the context of obesity improves metabolic phenotypes. Recently, drugs that preferentially decrease senescent cell burden, termed senolytics, have been identified (Kirkland, Tchkonia, Zhu, Niedernhofer, & Robbins, 2017). We discovered the first senolytics based on our observation that senescent cells rely on several survival pathways, including those regulated by PI3K/AKT‐, p53/p21/serpine‐, HIF‐1α‐, and BCL‐2/BCL‐XL‐family components, to confer resistance to their pro‐apoptotic SASP and intracellular cell damage signals (Zhu et al., 2016,2015). Knowing this, we identified dasatinib (D) and quercetin (Q) as orally bioactive drugs that transiently target these survival pathways to induce apoptosis preferentially in senescent cells (Zhu et al., 2015). Subsequently, we and others found that navitoclax, (ABT263, which targets Bcl‐xL, Bcl‐2, and Bcl‐w but not Mcl‐1), is also senolytic (Chang et al., 2016; Zhu et al., 2016). We showed that D and Q, alone and in combination, cause apoptosis in senescent cells without significant effects in quiescent or proliferating cells (Xu et al., 2018; Zhu et al., 2015). Senolytics do not prevent the generation of senescent cells and they are effective when administered intermittently, which could help to mitigate any potential negative effects of senescent cell removal, such as delayed wound healing (Demaria et al., 2017; Zhu et al., 2015). We employed the combination of D plus Q (D + Q) in our studies for the following reasons. (a) In our hands, no senolytic investigated thus far targets all types of senescent cells (Kirkland & Tchkonia, 2017). For example, unlike navitoclax (ABT263), fisetin, A1331852, A1155463 (Zhu et al., 2017,2016,2015), or Q on its own, D selectively targets senescent adipose progenitors (Zhu et al., 2015), a key cell type for adipose tissue and metabolic function (Tchkonia et al., 2013). (b) On the other hand, Q, unlike D, is effective against senescent endothelial cells (Zhu et al., 2015), a cell type implicated in vascular complications of diabetes (Caballero, 2003). (c) D + Q is effective in alleviating multiple age‐ and senescence‐associated disorders, including many that are frequent complications or comorbidities of diabetes in preclinical animal models; these comorbidities include arteriosclerosis, vascular hyporeactivity, osteoporosis, hepatic steatosis, physical dysfunction, neurodegeneration, and neuropsychiatric dysfunction (Farr et al., 2017; Kirkland & Tchkonia, 2017; Kirkland et al., 2017; Musi et al., 2018; Ogrodnik et al., 2017,2019; Roos et al., 2016; Xu et al., 2018). (d) Navitoclax and other BCL‐2 family member inhibitors can be toxic, for example, causing severe thrombocytopenia, which can occur even with intermittent dosing (Wilson et al., 2010). Navitoclax can also cause neutropenia, complicating interpretation of whether its effects are due to senolytic activity or immune system suppression. For these reasons, we elected to focus on D + Q. Here, we characterize the effects of eliminating senescent cells on obesity‐induced derangements in adipose tissue function and glucose homeostasis. To do this, we used both transgenic mouse models and treatment with the senolytics, D + Q. Our findings support the idea that senescent cells could be a novel therapeutic target for treating obesity‐induced metabolic dysfunction. RESULTS Senescent cells accumulate in visceral fat in obesity We used two transgenic mouse models from which senescent cells can be selectively cleared: (a) p16‐3MR mice, in which a long p16Ink4a‐promoter sequence drives expression of a trimodal reporter‐killer fusion protein (3MR), allowing senescent cell killing by ganciclovir (GCV) and identification by whole‐body luminescence (Demaria et al., 2014) and (b) INK‐ATTAC mice, in which a truncated p16Ink4a‐promoter sequence drives expression of a vFKBP‐caspase‐8‐FLAG fusion protein that can be activated by AP20187, a vFKBP dimerizer, to cause senescent cell apoptosis (Baker et al., 2011). Cells that highly express p16Ink4a are targeted in the INK‐ATTAC and p16‐3MR models. However, not all cells with high p16Ink4a expression are senescent, and not every senescent cell highly expresses p16Ink4a (Hall et al., 2017; Okuma, Hanyu, Watanabe, & Hara, 2017), limiting the sensitivity and specificity for senescent cell killing in these mouse models. Therefore, we used an additional distinct, potentially translatable approach for eliminating senescent cells, that is, senolytic drugs, which target anti‐apoptotic pathways in senescent cells and do not depend on p16Ink4a expression to reduce senescent cell burden (Kirkland et al., 2017; Zhu et al., 2015). Obesity was induced either by high‐fat diet (diet‐induced obesity, DIO, with ad libitum chow‐fed controls) or by genetic means in leptin receptor knockout (db/db) mice (Supporting Information Figure S1). Senescent cell abundance, as measured by luciferase activity in p16‐3MR mice, increased in response to DIO compared to chow‐fed mice (Figure 1a–c and Supporting Information Figure S2a,b). Bioluminescent imaging (BLI) in ex vivo tissues

Read the complete text